Abrazane more effective than Taxotere
Reuters notes that Abraxis (maker of Abraxane) published interim data showing tumors were more responsive to Abraxane and patients showed fewer side effects than with competing drug Taxotere.
Interim analysis of the 300-patient Phase II trial showed that 61 percent to 72 percent of patients treated weekly with a low dose and high dose, respectively, of Abraxane responded to the drug, compared with 36 percent given Taxotere every three weeks, the company said.
A dose of Abraxane give once every three weeks resulted in a response rate of just 33 percent.
A Phase III trial is scheduled for the first half of 2007. Both drugs are forms of pacilataxel, developed with the goal of interfering with cancer cell growth.